Compassionate Use of Concizumab if You Have Haemophilia
- Conditions
- Congenital Haemophilia
- Registration Number
- NCT04921956
- Lead Sponsor
- Novo Nordisk A/S
- Brief Summary
The compassionate use programme will give participants concizumab for free, even though it is not yet approved by health authorities. This is because participants need this medicine to treat their haemophilia properly. The programme will check that participants are safe and that the medicine works for them. The programme may last for years. Participants will take one injection under their skin every day. Participants will have 4-5 visits with the study doctor for the first half year. After that they will have 1 visit every half year. At all clinic visits participants will have blood samples taken. Participants will fill in a diary between the visits.
A patient is considered to have completed the programme when any of the following criteria occurred first: 1) when the patient is included in a clinical trial with concizumab or 2) up to 6 months after concizumab is commercially available in the patient's country and approved for the patient (The time span of 6 months should provide ample time for the patient to obtain concizumab commercially) or 3) the sponsor decides to discontinue concizumab clinical development for the patient's population.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- AVAILABLE
- Sex
- All
- Target Recruitment
- Not specified
-
Informed consent obtained before any programme-related activities. Programme-related activities are any procedures that are carried out as part of the programme.
-
Patients with congenital haemophilia:
- severe haemophilia A (coagulation factor VIII (FVIII) less than 1%) or moderate/severe haemophilia B (coagulation factor IX (FIX) less than or equal to 2%) without inhibitors or
- any haemophilia severity with documented history of inhibitors (more than or equal to 0.6 bethesda unit (BU)) who cannot be treated satisfactorily with authorised and marketed medicines (example: due to inhibitors or allergic reactions to factor-containing products, or due to poor venous access), and who are not able to enrol in clinical trials designed to support the development and registration of concizumab medicines (example: due to inhibitors or allergic reactions to factor-containing products, or due to poor venous access) as per investigator and Novo Nordisk assessment.
-
The potential benefit for the individual patient justifies the potential risks of treatment.
- Known or suspected hypersensitivity to investigational medicinal product or related products.
- Any condition (current or medical history), which in the investigator's or Novo Nordisk's opinion might jeopardise patient's safety or compliance with the protocol.
Study & Design
- Study Type
- EXPANDED_ACCESS
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (22)
University of California San Francisco UCSF
🇺🇸San Francisco, California, United States
Children's Hospital Los Angeles - Endocrinology
🇺🇸Los Angeles, California, United States
Memorial Health University Medical Center
🇺🇸Savannah, Georgia, United States
Childrens Hospital of Chicago
🇺🇸Chicago, Illinois, United States
Southern Specialty Clinic
🇺🇸Flowood, Mississippi, United States
Louisiana Ctr for Adv Med-LCAM
🇺🇸Madison, Mississippi, United States
The Children's Mercy Hospital
🇺🇸Kansas City, Missouri, United States
Children's Nebraska
🇺🇸Omaha, Nebraska, United States
Connecticut Children's Medical Center
🇺🇸Hartford, Connecticut, United States
Georgetown University Medical Center
🇺🇸Washington, District of Columbia, United States
Indiana Hemophilia-Thromb Ctr
🇺🇸Indianapolis, Indiana, United States
Children's Hospital of Michigan
🇺🇸Detroit, Michigan, United States
Penn State Hershey Medical Center
🇺🇸Hershey, Pennsylvania, United States
BI-LO Chrt Childn's Cancer Ctr
🇺🇸Greenville, South Carolina, United States
Cook Children's Hospital-Hematology-Oncology
🇺🇸Fort Worth, Texas, United States
Texas Children's Hospital_Houston
🇺🇸Houston, Texas, United States
Univ TX Hlth Sci Ctr Houston
🇺🇸Houston, Texas, United States
ECU Sickle Cell Comp Clinic
🇺🇸Greenville, North Carolina, United States
Nationwide Children's Hospital
🇺🇸Columbus, Ohio, United States
Virginia Commonwealth University_Richmond_1
🇺🇸Richmond, Virginia, United States
UMHAT "Sveti Georgi" Clinica of Pediatric
🇧🇬Plovdiv, Bulgaria
Koagulationsmottagningen
🇸🇪Solna, Sweden